NDA 016269 · Hospira
Mannitol 25%
Mannitol · Injection · Osmotic Diuretic
Last checked: Nov 20, 2026Latest source record: Mar 17, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1967
Dec 22, 1967
Approved uses
2
Original approval plus efficacy supplements
Registered trials
387
88 Phase 3, 30 recruiting
FAERS reports
4,906
4,670 serious, 1,418 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 2, 2026.
Mannitol Injection is indicated for the reduction of: intracranial pressure and treatment of cerebral edema. elevated intraocular pressure. Mannitol Injection is an osmotic diuretic, indicated for the reduction of: intracranial pressure and treatment of cerebral edema. (1) elevated intraocular pressure. (1)
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 17, 2020 Supplement 56 · Efficacy LabelLetter
- Dec 22, 1967 Original approval · Type 5 - New Formulation or New Manufacturer
6 products under this application
- MANNITOL 25% · MANNITOL 12.5GM/50ML · INJECTABLE, INJECTION · Discontinued
- MANNITOL 15% · MANNITOL 15GM/100ML · INJECTABLE, INJECTION · Discontinued
- MANNITOL 5% · MANNITOL 5GM/100ML · INJECTABLE, INJECTION · Discontinued
- MANNITOL 25% · MANNITOL 12.5GM/50ML · INJECTABLE, INJECTION · Prescription · TE AP
- MANNITOL 20% · MANNITOL 20GM/100ML · INJECTABLE, INJECTION · Discontinued
- MANNITOL 10% · MANNITOL 10GM/100ML · INJECTABLE, INJECTION · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Mannitol" as an intervention, any sponsor and status, largest first.
- Key Diagnostic & Therapeutic Technologies for Severe Acute High Altitude Disease (SAHAD): Integration and ApplicationPivotal-lookingNot yet recruiting
Tibet Autonomous Region People's HospitalAcademic, hospital or other
NCT07639931 · 3,035 participants (planned) · Start Jul 1, 2026 · Primary completion Dec 20, 2028
Drug: Multicenter study of HAPE group:NO Group · For: Severe High Altitude Pulmonary Edema; Severe High Altitude Cerebral Edema
Sites: Lhasa, China
- Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years OldPivotal-lookingCompleted
Shanghai Institute Of Biological ProductsIndustry
NCT05158777 · 2,480 participants · Start Feb 13, 2022 · Primary completion Nov 14, 2022
Drug: Live attenuated varicella vaccines manufactured by Shanghai Institute of Biological Products Co.,Ltd.; Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd · For: Varicella
Sites: Zhenzhou, China
- A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaPivotal-lookingRecruiting
Global Coalition for Adaptive ResearchAcademic, hospital or other
NCT03970447 · 2,250 participants (planned) · Start Jul 30, 2019 · Primary completion Jun 2028
Drug: Temozolomide; Lomustine and 8 more · For: Glioblastoma
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 63 sites in all
- Wheeze and Intermittent TreatmentPivotal-lookingCompleted
Queen Mary University of LondonAcademic, hospital or other
NCT01142505 · 1,358 participants · Start Nov 2010 · Primary completion Feb 2014
Drug: Mannitol; Montelukast · For: Wheezing
Sites: London, United Kingdom
- Acetaminophen-Mannitol Injection and Postoperative DeliriumPivotal-lookingRecruiting
Xiangya Hospital of Central South UniversityAcademic, hospital or other
NCT07235995 · 1,092 participants (planned) · Start Feb 2, 2026 · Primary completion Jan 31, 2027
Drug: Acetaminophen group; Sufentanil group · For: Postoperative Delirium
Sites: Changsha, China
- Adaptive COVID-19 Treatment Trial 2 (ACTT-2)Pivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT04401579 · 1,033 participants · Start May 8, 2020 · Primary completion Jul 31, 2020
Drug: Remdesivir; Baricitinib · For: COVID-19
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 71 sites in all
- Adaptive COVID-19 Treatment Trial 4 (ACTT-4)Pivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT04640168 · 1,010 participants · Start Dec 2, 2020 · Primary completion May 18, 2021
Drug: Baricitinib; Dexamethasone and 1 more · For: COVID-19
Sites: Birmingham, Alabama; Fresno, California; La Jolla, California · 72 sites in all
- Transfusion-requirements in Septic Shock TrialPivotal-lookingCompleted
Scandinavian Critical Care Trials GroupAcademic, hospital or other
NCT01485315 · 1,005 participants · Start Nov 2011 · Primary completion Mar 2014
Drug: SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion; SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion · For: Septic Shock
Sites: Aalborg, Denmark; Aarhus, Denmark; Copenhagen, Denmark · 32 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pain621
- renal failure592
- anxiety502
- injury495
- drug ineffective484
- stress473
- unevaluable event470
- fear430
- death415
- renal impairment394
- off label use393
- emotional distress386
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 116 |
| 2005 | 79 |
| 2006 | 89 |
| 2007 | 59 |
| 2008 | 87 |
| 2009 | 73 |
| 2010 | 105 |
| 2011 | 578 |
| 2012 | 255 |
| 2013 | 106 |
| 2014 | 144 |
| 2015 | 123 |
| 2016 | 223 |
| 2017 | 242 |
| 2018 | 215 |
| 2019 | 187 |
| 2020 | 220 |
| 2021 | 304 |
| 2022 | 376 |
| 2023 | 394 |
| 2024 | 395 |
| 2025 | 316 |
| 2026 | 219 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Head-To-Head Comparison of Biologic Efficacy in Asthma: What Have We Learned?
Lipworth BJ, Greig R, Chan R, et al. · Allergy 2025 · Comparative Study, Meta-Analysis
- Comparing the effects of mannitol and hypertonic saline in severe traumatic brain injury patients with elevated intracranial pressure: a systematic review and meta-analysis.
Karamian A, Seifi A, Lucke-Wold B · Neurol Res 2024 · Systematic Review, Meta-Analysis
- Hypertonic Saline Versus Mannitol for Traumatic Brain Injury: A Systematic Review and Meta-analysis With Trial Sequential Analysis.
Schwimmbeck F, Voellger B, Chappell D, et al. · J Neurosurg Anesthesiol 2021 · Comparative Study, Meta-Analysis
- Hypertonic saline for traumatic brain injury: a systematic review and meta-analysis.
Gharizadeh N, Ghojazadeh M, Naseri A, et al. · Eur J Med Res 2022 · Meta-Analysis, Systematic Review
- Effectiveness of hypertonic saline infusion in management of traumatic brain injury: an updated systematic review and meta-analysis of randomized controlled trials.
Cai L, He W · Brain Inj 2024 · Systematic Review, Meta-Analysis
- Transcutaneous vagal nerve stimulation protects against stress-induced intestinal barrier dysfunction in healthy adults.
Mogilevski T, Rosella S, Aziz Q, et al. · Neurogastroenterol Motil 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Pfizer · Also marketed as Mannitol 15%, Mannitol 5%, Mannitol 20%, Mannitol 10%
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.